title: The clinical effects of dendritic cell vaccines combined with cytokine-induced killer cells intraperitoneal injected on patients with malignant ascites.
abstract: Malignant ascites (MA) is a pathological condition due to a variety of primary abdominal and extra-abdominal neoplasms. It is a primary cause of morbidity and presents many difficulties in evaluation and treatment. In this study we used dendritic cell vaccines combined with cytokine-induced killer (CIK) cells intraperitoneal injected in patients with MA, and evaluated the safety and efficacy of this treatment. The results showed that the percentage of CD3(+) CD56(+) CIK cells after treatment increased significantly while the percentage of CD4(+) CD25(+) Treg cells decreased (P < 0.05). The clinical response rate (RR) was 40.9% and disease control rate (DCR) was 77.3%. We then studied and identified the mechanisms of the anti-tumor effects of the vaccines by analyzing a series of cytokines that are commonly involved in tumor progression and ascitic development including granulocyte macrophage colony stimulating factor (GM-CSF), interleukin-10 (IL-10), interferon-γ (IFN-γ), tumor necrosis factor-α (TGF-α), tumor necrosis factor-β (TGF-β), Vascular endothelial growth factor (VEGF) and monocyte chemotactic protein-1 (MCP-1). These data demonstrated that intraperitoneal injection with DC vaccines combined with CIK cells in patients with malignant peritoneal effusion is safe and feasible. This therapy modality can achieve a certain clinical benefit even in patients resistant to conventional treatments.
authors.affiliation: Department of Tumor Biological Therapy, 81 Hospital of PLA Nanjing 210002, Jiangsu, People's Republic of China.
authors.forename: Yue-Qin
authors.initials: YQ
authors.lastname: Ai
authors.affiliation: Department of Tumor Biological Therapy, 81 Hospital of PLA Nanjing 210002, Jiangsu, People's Republic of China.
authors.forename: Kai
authors.initials: K
authors.lastname: Cai
authors.affiliation: Department of Tumor Biological Therapy, 81 Hospital of PLA Nanjing 210002, Jiangsu, People's Republic of China.
authors.forename: Jian-Hua
authors.initials: JH
authors.lastname: Hu
authors.affiliation: Department of Tumor Biological Therapy, 81 Hospital of PLA Nanjing 210002, Jiangsu, People's Republic of China.
authors.forename: Long-Wei
authors.initials: LW
authors.lastname: Jiang
authors.affiliation: Department of Tumor Biological Therapy, 81 Hospital of PLA Nanjing 210002, Jiangsu, People's Republic of China.
authors.forename: Yan-Rong
authors.initials: YR
authors.lastname: Gao
authors.affiliation: Department of Tumor Biological Therapy, 81 Hospital of PLA Nanjing 210002, Jiangsu, People's Republic of China.
authors.forename: Hua
authors.initials: H
authors.lastname: Zhao
authors.affiliation: Department of Tumor Biological Therapy, 81 Hospital of PLA Nanjing 210002, Jiangsu, People's Republic of China.
authors.forename: Shao-Chang
authors.initials: SC
authors.lastname: Jia
keywords: Dendritic cell; cytokine-induced killer cell; cytokines; immunotherapy; malignant ascites